Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9

Abstract

Overexpression of mac25 in the prostate cancer cell line M12 effects a dramatic reversal of the transformed phenotype. cDNA array analysis of RNA from cells overproducing the mac25 protein (M12/mac25) indicated upregulation of the sex determining transcription factor SOX9. In this study, we have confirmed increased expression of SOX9 in M12/mac25 cells and have further investigated the physiological effects of increased SOX9 production. Greatly increased levels of SOX9 RNA and mature protein were demonstrated in cells transfected with a SOX9 cDNA (M12/SOX9), and gel mobility shift assays confirmed binding of nuclear protein from these cells to an oligonucleotide containing the SOX9 consensus binding sequence. M12/SOX9 cells assumed the spindle-shaped morphology characteristic of M12/mac25 cells, suggesting that SOX9 mediates some effects of mac25. Elevated expression of SOX9 resulted in a decreased rate of cellular proliferation, cell cycle arrest in G0/G1, and increased sensitivity to apoptosis. Tumor development in athymic nude mice was inhibited by 80%. Finally, prostate-specific antigen and the androgen receptor, two genes whose expression is characteristic of differentiated cells, were both upregulated in M12/SOX9 cells. These data indicate that SOX9 contributes to growth regulation by mac25 via inhibition of cell growth and promotion of differentiation.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Afonja O, Raaka BM, Huang A, Das S, Zhao X, Helmer E, Juste D and Samuels HH . (2002). Oncogene, 21, 7850–7860.

  • Bae VL, Jackson-Cook CK, Maygarden SJ, Plymate SR, Chen J and Ware JL . (1998). Prostate, 34, 275–282.

  • Bowles J and Koopman P . (2001). Genome Biol., 2, 10251–10254.

  • Burger A, Zhang X, Li H, Ostrowski J, Beatty B, Venanzoni M, Papas T and Seth A . (1997). Oncogene, 16, 2459–2467.

  • Chomczysnki P and Sacchi N . (1987). Anal. Biochem., 162, 156–159.

  • Clarkson MJ and Harley VR . (2002). Trends Endocrinol. Metab., 13, 106–111.

  • Damon SE, Maddison L, Ware JL and Plymate SR . (1998). Endocrinology, 139, 3456–3464.

  • Drivdahl RH, Sprenger CC, Trimm K and Plymate SR . (2001). Endocrinology, 142, 1990–1998.

  • Feinberg AP and Vogelstein B . (1983). Anal. Biochem., 132, 6–13.

  • Fourney RM, Day RS and Paterson MC . (1989). Focus, 10, 5–7.

  • Graff JR, Konicek BW, McNulty MN, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GF, Vessella RL and Neubauer BL . (2000). J. Biol. Chem., 275, 24500–24505.

  • Graves JA . (1998). BioEssays, 20, 264–269.

  • Healy C, Uwanogho D and Sharpe PT . (1999). Dev. Dyn., 215, 69–78.

  • Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S and Binoux M . (1986). Anal. Biochem., 154, 138–143.

  • Hwa V, Tomasini-Sprenger C, Bermejo AB, Rosenfeld RG and Plymate SR . (1998). J. Clin. Endocinol., 83, 4355–4362.

  • Kanai Y and Koopman P . (1999). Hum. Mol. Genet., 8, 691–696.

  • Kato M, Sato H, Tsukada T, Ikawa Y, Aizawa S and Nagayoshi MA . (1996). Oncogene, 12, 1361–1364.

  • Kent J, Wheatley SC, Andrews JE, Sinclair AH and Koopman P . (1996). Development, 122, 2813–2822.

  • Kishibe J, Yamada S, Okada Y, Sato J, Ito A, Miyazaki K and Sugahara K . (2000). J. Biol. Chem., 275, 15321–15329.

  • Komatsu K, Okazaki Y, Tateno M, Kawai J, Konno H, Kusakabe K, Yoshiki A, Muramatsu M, Held WA and Hayashizaki Y . (2001). Biochem. Biophys. Res. Commun., 276, 109–117.

  • Koopman P, Bullejos M and Bowles J . (2001). J. Exp. Zool., 290, 463–474.

  • Lefebvre V, Huang W, Harley VR, Goodfellow PN and deCrombrugghe B . (1997). Mol. Cell. Biol., 17, 2336–2346.

  • Lehrach H, Diamond D, Wozney JM and Boedtker H . (1977). Biochemistry, 16, 4743–4749.

  • Li N, Oberley TD, Oberley LW and Zhong W . (1998). J. Cell. Physiol., 175, 359–369.

  • Lin HK, Yeh, Kang HY and Chang C . (2001). Proc. Natl. Acad. Sci. USA, 98, 7200–7205.

  • Lopez-Bermejo A, Buckway CK, Devi GR, Hwa V, Plymate SR, Oh Y and Rosenfeld RG . (2000). Endocrinology, 141, 4072–4080.

  • Lu S, Jenster G and Epner DE . (2000). Mol. Endocrinol., 14, 753–760.

  • Marshall OJ and Harley VR . (2000). Mol. Genet. Metab., 71, 455–462.

  • Miller GJ . (1999). Cancer Metastasis Rev., 17, 353–360.

  • Murakami S, Kan M, McKeehan WL and deCrombrugghe B . (2000). Proc. Natl. Acad. Sci. USA, 97, 1113–1118.

  • Murillo H, Huang H, Schmidt L, Smith DI and Tindall DJ . (2001). Endocrinology, 142, 4795–4805.

  • Murphy M, Pykett M, Harnish P, Zang K and George D . (1993). Cell Growth Differ., 4, 715–722.

  • Oberley LW . (2001). Antioxidants Redox Signal., 3, 461–472.

  • Oh Y, Nagalla S, Yamanaka Y, Kim H, Wilson E and Rosenfeld R . (1996). J. Biol. Chem., 271, 30322–30325.

  • Olney PN, Kean LS, Graham D, Elsas LJ and May KM . (1999). Am. J. Med. Genet., 84, 20–24.

  • Panda D, Miao D, Lefebvre V, Hendy G and Goltzman D . (2001). J. Biol. Chem., 276, 41229–41236.

  • Peehl DM and Stamey TA . (1986). In vitro Cell Dev., 22, 82–90.

  • Plymate SR, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Zhang Y, Oberley LW, Zhong W, Drivdahl RH and Oberley TD . (2003). Oncogene, 22, 1024–1034.

  • Preiss S, Argentaro A, Clayton A, John A, Jans D, Ogata T, Nagai T, Barroso I, Schafer A and Harley VR . (2001). J. Biol. Chem., 276, 27864–27872.

  • Reinikaninen P, Palvimo JJ and Janne OA . (1996). Endocrinology, 137, 4351–4357.

  • Rhee SG, Bae Y, Lee SR and Kwon J . (2000). Science Sign. Trans. Knowl. Environ., 53, 1–6.

  • Rosenthal DS, Ding R, Simbulan-Rosenthal CM, Vaillancourt JP, Nicholson DW and Smulson M . (1997). Exp. Cell Res., 232, 313–321.

  • Sambrook J, Fritsch EF and Maniatis T . (1989). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory: Cold Spring Harbor, NY.

    Google Scholar 

  • Simbulan-Rosenthal CM, Rosenthal D, Luo R and Smulson M . (1999). Mol. Cell. Biochem., 193, 137–148.

  • Spokony RF, Aoki Y, Saint-Germain N, Magner-Fink E and Saint-Jeannet JP . (2002). Development, 129, 421–432.

  • Sprenger CC, Damon SE, Hwa V, Rosenfeld RG and Plymate SR . (1999). Cancer Res., 59, 2370–2375.

  • Sprenger CC, Vail ME, Evans K, Smurdak J and Plymate SR . (2002). Oncogene, 21, 140–147.

  • Swisshelm K, Ryan K, Tsuchiya K and Sager R . (1995). Proc. Natl. Acad. Sci. USA, 92, 4472–4476.

  • Tran CP, Lin C, Yamashiro J and Reiter RE . (2002). Mol. Cancer Res., 1, 113–121.

  • Ulrich A, Berman CH, Dull TJ, Gray A and Lee JM . (1984). EMBO J., 3, 361–364.

  • Vidal VP, Chaboissier MC, Rooij DG and Schedl A . (2001). Nat. Genet., 28, 216–217.

  • Vleminckx K and Kemmler R . (1999). BioEssays, 21, 211–220.

  • Wilson EM, Oh Y, Hwa V and Rosenfeld RG . (2001). J. Clin. Endocrinol. Metab., 86, 4504–4511.

  • Wilson HMP, Birnbaum R, Poot M, Quinn LS and Swisshelm K . (2002). Cell Growth Differ., 13, 205–213.

  • Yeh S, Lin HK, Kang HY, Thin TH, Lin MF and Chang C . (1999). Proc. Natl. Acad. Sci. USA, 96, 5458–5463.

Download references

Acknowledgements

This research was supported by PO1-CA85859 (to SRP and PSN), and RO1-56283 and Veterans Affairs Merit Review Program to SRP.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stephen R Plymate.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Drivdahl, R., Haugk, K., Sprenger, C. et al. Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9. Oncogene 23, 4584–4593 (2004). https://doi.org/10.1038/sj.onc.1207603

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207603

Keywords

This article is cited by

Search

Quick links